Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatocyte growth factor activator serine protease (HGFAC)
- Target
- HGFAC
- Molecular classification
- Enzyme, Serine protease, Peptidase S1 family, Trypsin-like serine protease
01
Overview
**Hepatocyte growth factor activator serine protease (HGFAC)** is an enzyme belonging to the serine protease S1 family that plays a critical role in proteolytically activating the latent form of hepatocyte growth factor (HGF), converting it into its biologically active heterodimeric form. HGFAC is itself activated in response to tissue injury, linking the coagulation/fibrinolytic system to tissue regeneration by facilitating HGF activity. The HGF/HGFAC axis is involved in processes like cell proliferation, migration, and tissue repair, and is implicated in cancer progression when aberrantly regulated[1][2][3][4][5][7][8].
- Other names
- HGF activatorHGFAHGFACHepatocyte growth factor activatorHGFA serine proteaseHGFAPSerine protease HGFACHepatocyte growth factor activator serine proteaseHepatocyte growth factor activator short chainHepatocyte growth factor activator long chain
02
Mechanism of action
Inhibition of serine protease activity to block activation of HGF; this indirectly reduces signaling through the HGF/Met pathway, which is implicated in cell growth, migration, invasion, and tumorigenesis[2][9].
03
Biological functions
Proteolytic activation of hepatocyte growth factorRegulation of cellular proliferationRegulation of tissue regeneration and repairRegulation of cell migrationBlood coagulation linkActivation of growth factor signaling
04
Disease associations
CancerTissue regenerationWound healingMalignant peripheral nerve sheath tumorPotential role in fibrosisOther disorders related to aberrant HGF/Met signaling
05
Safety considerations
Therapeutic inhibition of HGFAC could impair tissue repair and regeneration, possibly increasing risk for poor wound healing or interference with normal HGF-mediated homeostasis; alterations in blood coagulation pathways are a theoretical concern[1][2].
06
Interacting drugs
No approved small-molecule inhibitors or drugs currently established; some experimental inhibitors (such as Kunitz-type protease inhibitors and HGF activator inhibitor-1B) have been studied for their potential to inhibit HGFAC activity[2][9].
07
Biomarkers
No widely established clinical biomarkers; experimental use in cancer and tissue regeneration studies as a biomarker for activation of the HGF/Met pathway[4].
Beyond the preview
Go deeper on Hepatocyte growth factor activator serine protease (HGFAC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepatocyte growth factor activator serine protease (HGFAC).